Key facts
- RespirAI’s last known valuation is $7.8M (Aug 2024).
- It has raised $3.6M; the latest was Later Stage VC ($1.0M) in Mar 2026.
- Notable investors include Innovation Authority, Invest Nebraska, Nebraska Angels, The Nebraska Department of Economic Development, eHealth Ventures (Israel).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for RespirAI
- ·The full record, as it builds
Funding rounds
No funding rounds for RespirAI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RespirAI
Developer of a passive sensor-based wearable device intended to monitor and manage chronic respiratory diseases. The company's device utilizes artificial intelligence to provide reliable technology for monitoring chronic respiratory diseases and aims to improve the outcomes of patients' respiratory deterioration by detecting early exacerbations of chronic diseases, enabling doctors and care providers to improve patients' quality of life.
- Sector
- Healthcare
- HQ
- Omaha, NE, United States
- Founded
- 2020
- Employees
- 8
- Website
- respirai.com/
- Ownership
- Privately Held (backing)
RespirAI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RespirAI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RespirAI in its N-PORT filings yet. We sweep new filings monthly.